Short ANAQUANT presentation

2. 2

3. 3
ADCs
characterization
HCPs
Contaminents
PKPD/DMPK
Quantification in
complex matrix
Insulins
Customized
development of
Absolute and
sensitive
quantification
methods in
various biological
matrices
Routine
bioanalyses of
your samples

4. 4

5. 5
Alternative to immunassays
Multiplexing
Absolute quantification
Short assay development time
Minimal sample volume
Biological complex matrices analysis
(serum, plasma, urine, tissue)

6. customized services.
secure your budget
6
Assay
development
Assay
validation
Technology
transfer
Sample
bioanalysis
Feasibility
study

7. 7

8. 8
4.2 6.2 8.2
0
3500
7000

9. 9
HCP quantitation from 6 000 to 6 ppm
1,0
2,0
4,0
8,0
16,0
32,0
64,0
128,0
256,0
512,0
1024,0
2048,0
4096,0
8192,0
Step1 Step2 Step3
HCPproteinconcentration(ppm)
Production steps

12. 12

13. 13

14. Clinical quantitation of prostate specific antigen biomarker in the low nanogram/mL
range by conventional bore liquid chromatography-tandem mass spectrometry
(MRM) coupling and correlation with ELISA tests
Multiple reaction monitoring cubed for protein quantification at the low
nanogram/milliliter level in nondepleted human serum.
The current status of clinical proteomics and the use of MRM and MRM(3) for
biomarker validation
Absolute quantification of podocin, a potential biomarker of glomerular injury in
human urine, by liquid chromatography-multiple reaction monitoring cubed mass
spectrometry.

15. To discuss about your project please
contact us:
www.anaquant.com
tanguy.fortin@anaquant.com
+33 (0)6.64.22.13.50
quentin.enjalbert@anaquant.com
+33 (0)7.85.12.17.85